These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29377167)

  • 1. Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Luo J; Lindstrom J
    Ann N Y Acad Sci; 2018 Feb; 1413(1):76-81. PubMed ID: 29377167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AChR-specific immunosuppressive therapy of myasthenia gravis.
    Luo J; Lindstrom J
    Biochem Pharmacol; 2015 Oct; 97(4):609-619. PubMed ID: 26215875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.
    Luo J; Kuryatov A; Lindstrom JM
    Ann Neurol; 2010 Apr; 67(4):441-51. PubMed ID: 20437579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis.
    Luo J; Lindstrom J
    J Immunol; 2014 Nov; 193(10):5044-55. PubMed ID: 25288571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.
    Luo J; Lindstrom J
    Autoimmunity; 2012 May; 45(3):245-52. PubMed ID: 21950318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenogenicity of the main immunogenic region.
    Lindstrom J; Luo J
    Ann N Y Acad Sci; 2012 Dec; 1274(1):9-13. PubMed ID: 23252892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
    Fuchs S; Aricha R; Reuveni D; Souroujon MC
    J Autoimmun; 2014 Nov; 54():51-9. PubMed ID: 24970384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis.
    Nakamura R; Makino T; Hanada T; Terakawa M; Nagahira K; Yamate J; Shiraishi H; Motomura M
    J Neuroimmunol; 2018 Jul; 320():64-75. PubMed ID: 29759142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
    Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
    Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.
    Li Z; Li M; Wood K; Hettwer S; Muley SA; Shi FD; Liu Q; Ladha SS
    Muscle Nerve; 2018 May; 57(5):814-820. PubMed ID: 29193204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylcholine receptors and myasthenia.
    Lindstrom JM
    Muscle Nerve; 2000 Apr; 23(4):453-77. PubMed ID: 10716755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
    Yao X; Zhao J; Kong Q; Xie X; Wang J; Sun B; Xu L; Mu L; Li H
    Immunol Invest; 2018 Oct; 47(7):712-724. PubMed ID: 29944018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis.
    Feferman T; Maiti PK; Berrih-Aknin S; Bismuth J; Bidault J; Fuchs S; Souroujon MC
    J Immunol; 2005 May; 174(9):5324-31. PubMed ID: 15843529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
    Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
    FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Grilled Nux Vomica on Differential RNA Expression Profile of Gastrocnemius Muscle and Toll‑Like Receptor 4 (TLR-4)/Nuclear Factor kappa B (NF-κB) Signaling in Experimental Autoimmune Myasthenia Gravis Rats.
    Jiang XH; Chen Y; Ding YY; Qiu H; Zhou DY; Qiu CL
    Med Sci Monit; 2020 Feb; 26():e919150. PubMed ID: 32052794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
    Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
    Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.